Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

0.0982 -0.0058 (-5.58%)
Streaming Delayed Price Updated: 12:28 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Quince Therapeutics to Participate at Upcoming Investor Conferences
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 ↗
Quince Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 ↗
Quince Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 ↗
Quince Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Launches Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.